Cancer drug developer Flexus has closed a Celgene-backed series B round that boosted its overall funding to $38m.
US-based biopharmaceutical company Flexus Biosciences has closed a series B round backed by investors including pharmaceutical firm Celgene, which brought its overall funding to $38m to date.
The round also featured venture capital firms The Column Group and Kleiner Perkins Caufield & Byers, the latter of which incubated Flexus, providing series A financing for it in October 2013.
Flexus is developing small-molecule treatments for cancer that target the regulatory T cells which help enable tumours to evade the body’s immune…
